Sponsor hub
Eli Lilly and Company clinical trial failures
Review 124 stopped clinical trials from Eli Lilly and Company, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 46 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OTHER/UNKNOWN
- 54
- EFFICACY/FUTILITY
- 38
- OPERATIONAL
- 24
- SAFETY
- 8
Notable sponsors
- Eli Lilly and Company
- 124
Related phases
- Phase I
- 55
- Phase II
- 37
- Phase III
- 27
- Phase IV
- 5
Crawlable stopped-trial records
Open ExploreShowing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Prostatic Neoplasms trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint.
Phase III Migraine trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study terminated due to strategic business decision
Phase II Rheumatoid Arthritis trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The interim analysis data failed to demonstrate the intended treatment effect.
Phase I Dyslipidemias trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Participants were not dosed in Part B as per the protocol.
Phase III Migraine trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study terminated due to strategic business decision
Phase II Heart Failure trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
An interim was conducted and after review of available data, including efficacy evaluation of heart failure events, Lilly is terminating the study due to low likelihood of study success for this HFpEF patient population.
Phase III Covid19 trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study terminated due to an inability to enroll participants.
Phase II Rheumatoid Arthritis trial by Eli Lilly and Company. Stop reason: SAFETY.
Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.
Phase II Atopic Dermatitis trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
The decision to terminate the study was due to efficacy/effectiveness reasons.
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Trial was terminated due to an insufficient benefit/tolerability ratio
Phase I Solid Tumor trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
The study was terminated for lack of sufficient efficacy.
Phase I Solid Tumors trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Based on emerging nonclinical data, the study was terminated.
Phase II Chronic Kidney Disease trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group.
Phase II Obesity trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study terminated for strategic business reasons
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
COVID-19 pandemic.
Phase II Healthy trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study terminated for strategic business reasons
Phase II Obesity trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study terminated for strategic business reasons
Phase I Solid Tumor trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
The study was terminated due to business considerations
Phase III Breast Neoplasms trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study is terminated due to inability to enroll study participants
Phase II Nakajo-Nishimura Syndrome trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
The study was terminated due to efficacy/effectiveness reasons
Phase I Hypertriglyceridemia trial by Eli Lilly and Company. Stop reason: SAFETY.
The study was terminated due to a change in risk/benefit ratio, which no longer favoured continued development.
Phase II Systemic Lupus Erythematosus trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Study terminated due to lack of efficacy
Phase I Advanced Cancer trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study did not achieve its primary objective due to early termination of the study
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Following preplanned review of the safety and pharmacokinetic data from Part A, it was determined that sufficient data had been obtained. The decision was made to not proceed with Part B and the study was terminated early.
Phase I Healthy trial by Eli Lilly and Company. Stop reason: SAFETY.
Terminated due to safety findings
Phase I Healthy trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Study terminated due to lack of efficacy signal in atopic dermatitis participants.
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
HUAA study is terminated early due to a business decision.
Phase II Diabetic Peripheral Neuropathic Pain trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
The trial was slow to enroll, and the sponsor made a business decision to terminate the trial earlier than planned.
Phase I Diabetes Mellitus, Type 2 trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Slow enrollment
Phase I Synovial Sarcoma trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Study terminated for meeting protocol specified futility criteria.
Phase III Systemic Lupus Erythematosus trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data
Phase III Psoriasis trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
The study was terminated due to a strategic business decision made by the Sponsor.
Phase I Advanced Solid Tumor trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study terminated due to inadequate PK profile associated with the subcutaneous formulation.
Phase III Systemic Lupus Erythematosus trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
The sponsor made a business decision to withdraw the trial.
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Data from part 2 no longer deemed necessary for this program.
Phase I Myeloid Leukemia trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy
Phase I Healthy trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
At the protocol-specified interim analysis, the sponsor decided to stop the trial.
Phase III Atopic Dermatitis trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Terminated due to lack of alignment during regulatory negotiations.
Phase I Psoriasis trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Terminated due to liver findings
Phase II Chronic Spontaneous Urticaria trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The study was terminated for lack of efficacy after an interim analysis was performed
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Protocol stopping criteria (safety) were met.
Phase I Advanced Solid Tumor trial by Eli Lilly and Company. Stop reason: SAFETY.
The study was terminated due to an unexpected toxicity finding.
Phase I Solid Tumor trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
The study was terminated during dose escalation after a determination was made that the risk:benefit ratio no longer favored continued evaluation.
Phase I Solid Tumor trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study terminated due to strategic business decision by Eli Lilly and Company.
Phase IV Metastatic Breast Cancer trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Business decision based on the inability to enroll subjects into the trial
Phase IV Type 2 Diabetes trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study was stopped prior to study start date due to business decision.
Phase II COVID-19 trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Trial terminated for futility.
Phase III Ulcerative Colitis trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.
Phase II Atopic Dermatitis trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The study was terminated for lack of efficacy after an interim analysis was performed
Phase II Alzheimer's Disease trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Low likelihood of identifying a statistically significant treatment effect.
Phase II Non Small Cell Lung Cancer trial by Eli Lilly and Company. Stop reason: SAFETY.
The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit ratio is unfavorable.
Phase II Non-small Cell Lung Cancer Metastatic trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The study stopped due to lack of efficacy.
Phase II Lung Cancer trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Terminated due to lack of efficacy demonstrated in relevant participant population in other clinical trials.
Phase II Primary Biliary Cholangitis trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Study was terminated due to enrollment futility.
Phase II Breast Cancer trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study has been terminated due to slow enrollment
Phase II Non Small Cell Lung Cancer trial by Eli Lilly and Company. Stop reason: SAFETY.
The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.
Phase II Breast Cancer trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
New data suggests that insufficient target engagement would be achieved for efficacy.
Phase II Stage IV Non-small Cell Lung Cancer trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
To pursue broader program objectives in oncology.
Phase I Solid Tumor trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study terminated due to strategic business decision by Eli Lilly and Company.
Phase II Migraine Headache trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Due to efficacy results of interim analysis
Phase I Advanced Cancer trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
The withdrawal is due to a strategic realignment and is not related to any particular safety or efficacy concern.
Phase I Neoplasms trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
This trial was terminated early based on the lack of sufficient clinical efficacy observed.
Phase I Diabetes Mellitus, Type 1 trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Drug delivery was below target dose due to partial obstruction by aggregated particles.
Phase IV Fibromyalgia trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Terminated due to study design changes; zero patients enrolled.
Phase III Alzheimer's Disease trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal AD as defined by study protocol.
Phase II Rheumatoid Arthritis trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The trial was terminated after an interim analysis of efficacy and safety data did not warrant continuation of the trial.
Phase IV Diabetes Mellitus, Type 2 trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
The trial was terminated per protocol because of lack of feasibility.
Phase II Diabetes Mellitus, Type 2 trial by Eli Lilly and Company. Stop reason: SAFETY.
The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.
Phase III Muscular Dystrophy, Duchenne trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The study is being terminated for lack of efficacy
Phase III Alzheimer's Disease trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Solanezumab did not meet the study's primary endpoint.
Phase III Treatment Resistant Depression trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Interim assessment: Lack of efficacy
Phase II Attention Deficit Hyperactivity Disorder trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Terminated due to low 5 year completer number and not meeting primary objective.
Phase III Alzheimer's Disease trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
Phase III Hyperlipidemia trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study termination due to program termination.
Phase I Type 2 Diabetes Mellitus trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Lack of Efficacy
Phase III Cardiovascular Diseases trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Study termination due to insufficient efficacy.
Phase II Locally Advanced Squamous Non-Small Cell Lung Cancer trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
This was a strategic decision for business planning purposes and not out of concern for patient safety.
Phase III Sickle Cell Disease trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The study is being terminated for lack of efficacy.
Phase II Diabetic Kidney Disease trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Interim Assessment: Lack of Efficacy
Phase II Osteoarthritis, Knee trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Interim assessment: Lack of efficacy
Phase IV Metastatic Breast Cancer trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Strategic decision due to emerging new data for patients with HR+, HER2- metastatic breast cancer.
Phase I Solid Tumor trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Healthy Volunteers trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study terminated due to unacceptable pharmacokinetic (PK) profile.
Phase II Metastatic Clear Cell Renal Cell Carcinoma trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Study Terminated due to Insufficient Efficacy
Phase I Healthy Volunteers trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in some participants.
Phase I Acute Leukemia trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Primary objective has been met in the absence of clinically meaningful remissions
Phase II Benign Prostatic Hyperplasia trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
Terminated due to insufficient efficacy
Phase I Advanced Cancer trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Terminated based on safety results from another trial
Phase I Hypertension trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
injection site reaction burden
Phase I Metastases, Neoplasm trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Primary objective has been met; safety and pharmacokinetics have been characterized.
Phase I Osteoporosis, Postmenopausal trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Protocol stopping criteria (safety) were met.
Phase I Advanced Cancer trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
The pharmacokinetic properties of the molecule do not allow for further dose escalation or development.
Phase I Pancreatic Cancer trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
Study has been terminated due to slow enrollment.
Phase I Advanced Solid Tumors trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Study was terminated due to the termination of tasisulam development.
Phase I Small Cell Lung Carcinoma trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Change in clinical strategy.
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OPERATIONAL.
due to business decisions
Phase I Healthy trial by Eli Lilly and Company. Stop reason: OTHER/UNKNOWN.
Part B of the study no longer required due to new information on the study drug.